Health Care & Life Sciences » Pharmaceuticals | Sareum Holdings PLC

Sareum Holdings PLC | Income Statement

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
0.40
0.40
1.80
1.80
4.00
5.30
Gross Income
0.40
0.40
1.80
1.80
4.00
5.30
SG&A Expense
605.80
928.00
810.10
994.00
1,441.80
1,703.90
EBIT
606.10
928.40
811.90
995.80
1,445.80
1,709.30
Non Operating Income/Expense
-
150.00
135.40
122.60
20.00
-
Pretax Income
602.80
773.90
944.20
868.80
1,422.80
1,706
Income Tax
63.70
74.30
185.90
152.60
47.40
248.70
Equity in Affiliates
-
63.20
497.00
331.90
1,775.70
12.30
Consolidated Net Income
539.10
762.90
1,255.40
1,048.10
400.30
1,469.50
Net Income
539.10
762.90
1,255.40
1,048.10
400.30
1,469.50
Net Income After Extraordinaries
539.10
762.90
1,255.40
1,048.10
400.30
1,469.50
Net Income Available to Common
539.10
762.90
1,255.40
1,048.10
400.30
1,469.50
EPS (Basic)
0.00
0.00
0.00
0.00
0.00
-
Basic Shares Outstanding
1,494,114.00
1,693,479.40
1,941,676.60
2,524,944.70
2,645,224.00
2,705,771.90
EPS (Diluted)
0.00
0.00
0.00
0.00
0.00
-
Diluted Shares Outstanding
1,494,114.00
1,693,479.40
1,941,676.60
2,524,944.70
2,741,310.00
2,705,771.90
EBITDA
605.80
928.00
810.10
994.00
1,441.80
1,704
Non-Operating Interest Income
3.30
4.50
3.00
4.40
3.00
3.70

About Sareum Holdings

View Profile
Address
Unit 2A, Langford Arch
Cambridge Cambridgeshire CB22 3FX
United Kingdom
Employees -
Website http://www.sareum.co.uk
Updated 07/08/2019
Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. Its drug discovery pipeline includes Chk1, TYK2, and Aurora+FLT3 kinases. The company was founded by Timothy John Mitchell, David Hugh Williams, and John Charles Reader on August 1, 2003 and is headquartered in Cambridge, the United Kingdom.